Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;12(20):2825-2828.
doi: 10.1111/1759-7714.14113. Epub 2021 Aug 18.

Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy

Puyuan Xing  1 , Mengzhao Wang  2 , Jun Zhao  3 , Wei Zhong  2 , Yujia Chi  3 , Ziyi Xu  1 , Junling Li  1
Affiliations

Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy

Puyuan Xing et al. Thorac Cancer. 2021 Oct.

Abstract

Background: For advanced nonsquamous non-small cell lung cancer (NSCLC), the mechanisms of resistance to first-line immunotherapy are not clear. Immune checkpoint inhibitors (ICIs) in combination with agents targeting other pathways may serve as second-line therapy options. Apatinib (a vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor) could increase the efficacy of camrelizumab (an ICI agent). The efficacy and safety of this combination regimen as a second-line therapy for NSCLC patients after failure on first-line immunotherapy has not previously been evaluated.

Methods: In this single-arm, multicenter, phase II trial, metastatic nonsquamous NSCLC patients previously treated with single-agent ICI or ICI plus chemotherapy will be enrolled. Participants will receive intravenous camrelizumab 200 mg D1 and oral apatinib 250 mg D1-21 for a 21-day cycle. The study treatment will continue until disease progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint is progression-free survival by investigator. Secondary endpoints are overall survival, objective response rate, disease control rate, duration of response by investigator, quality of life, safety, and toxicity.

Conclusions: This trial will provide evidence of the benefit of treatment with camrelizumab combined with apatinib in advanced nonsquamous NSCLC patients who were previously treated with first-line immunotherapy.

Trial registration: ClinicalTrials.gov NCT04670913 NCT03689855 NCT04471428 NCT03976375.

Keywords: apatinib; camrelizumab; immune checkpoint inhibitors; non-small cell lung cancer; second-line treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed
    1. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong K‐K. Non‐small‐cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14:535–46. - PMC - PubMed
    1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non‐small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94. - PMC - PubMed
    1. National Comprehensive Cancer Network (NCCN) . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non‐Small Cell Lung Cancer Version 1.2021. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 25 Nov 2020.
    1. Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland Å, Han J‐Y, et al. Atezolizumab treatment beyond progression in advanced NSCLC: results from the randomized, phase III OAK study. J Thorac Oncol. 2018;13:1906–18. - PubMed

Publication types

Associated data